KMT2A and acute lymphoblastic leukemia: Median EFS in the PVEK‐treated groups ranged from 15.8 (MLL‐5) to 232 (ALL‐3) days (T‐C 10.9–225 days; T/C 3.2–34.6), with mice engrafted with seven out of eight PDXs achieving a median EFS well beyond the 3‐week treatment period and two PDXs (ALL‐3, MLL‐1) beyond 200 days (Figure 2E).